Omnihealth Practice

DIABETES & ENDOCRINOLOGY

Managing the early-onset type 2 diabetes mellitus: Target the major hurdles

29 Jun 2020

Preventing cardiovascular risk in patients with ACS and T2DM

30 Dec 2019

What not to ignore when diabetes interacts with acute and chronic kidney diseases: A local case sharing

30 Dec 2020

Managing the early-onset type 2 diabetes mellitus: Target the major hurdles

People with young-onset diabetes have a worse metabolic risk profile compared to those with late-onset disease. This group has higher risks for cardiovascular and kidney complications at any given age, driven by the longer disease duration.1 In Hong Kong, while the mortality rate decrease in people

29 Jun 2020

Dr. Luk, On-Yan Andrea

Associate Professor,
Department of Medicine & Therapeutics,
The Chinese University of Hong Kong

ENDO 2020

30 - 31 March 2020 |

San Francisco, United States

What not to ignore when diabetes interacts with acute and chronic kidney diseases: A local case sharing

While they may not necessarily have a causal relationship, both chronic kidney disease (CKD) and diabetes mellitus (DM) have become increasingly more prevalent worldwide.1 As these conditions could be risk factors for developing acute kidney injury (AKI),2 CKD and DM must be carefully managed to pre

30 Dec 2020

Dr. Cheung, Siu-Fai

Specialist in Nephrology

Semaglutide aids weight loss in adults with type 2 diabetes and reduces major adverse cardiovascular events

Weight control remains an indispensable component for the clinical management of type 2 diabetes mellitus (T2DM) in preventing cardiometabolic morbidity.1-3 People with T2DM who received weekly subcutaneous injection of semaglutide 2.4mg achieved superior and clinically meaningful reduction of body

08 Apr 2021

Anti-IL-21 and liraglutide combination could preserve β-cell function in type 1 diabetes, a recent phase 2 study suggests

Being an autoimmune disease, type 1 diabetes (T1D) is characterized by the infiltration of immune cells into the pancreas that causes the destruction of insulin-producing β-cells in the pancreatic islets of Langerhans.1 While it has been the mainstay therapy for patients with T1D since its discovery

08 Apr 2021

DIABETES & ENDOCRINOLOGY

No response to exercise? The gut microbiota is to blame

29 Feb 2020